(R)-3-((S)-1-Benzo[1,3]dioxol-5-yl-2-ethoxycarbonyl-ethylcarbamoyl)-piperidine-1-carboxylic acid tert-butyl ester | 184965-15-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (R)-3-((S)-1-Benzo[1,3]dioxol-5-yl-2-ethoxycarbonyl-ethylcarbamoyl)-piperidine-1-carboxylic acid tert-butyl ester
• CAS: 184965-15-9
• 化学式: C₂₃H₃₂N₂O₇
• 分子量: 448.516
• InChiKey: VNTNASKBNAQHAN-SJORKVTESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.17
• 重原子数：
  32.0
• 可旋转键数：
  6.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  103.4
• 氢给体数：
  1.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  (R)-3-((S)-1-Benzo[1,3]dioxol-5-yl-2-ethoxycarbonyl-ethylcarbamoyl)-piperidine-1-carboxylic acid tert-butyl ester 在 N-甲基吗啉 、 盐酸 、 lithium hydroxide 、 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 作用下， 生成 N-3-(4-piperidinepropionyl)-(R)-(-)-nipecotyl[(S)-3-amino-3-(3,4-methylenedioxyphenyl)]propionic acid
  参考文献：
  名称：

  Solid-phase parallel synthesis applied to lead optimization: Discovery of potent analogues of the GPIIb/IIIa antagonist RWJ-50042

  摘要：

  A study of beta-turn peptide mimetics, related to the C-terminal gamma-chain of fibrinogen and containing a nipecotic acid scaffold, led to RWJ-50042 (1), an interesting fibrinogen receptor (GPIIb/IIIa) antagonist. To enhance potency, we employed solid-phase parallel synthesis for the preparation of over 200 analogues in a protocol of optimization cycles. This strategy produced several promising nipecotamide analogues, such as 25, which is 35 times more potent than 1 in vitro. Copyright (C) 1996 Elsevier Science Ltd.

  DOI：

  10.1016/0960-894x(96)00438-6
• 作为产物：
  描述：

  (E)-3-(1,3-苯并二氧戊环-5-基)丙烯酸乙酯 在 palladium dihydroxide N-甲基吗啉 、 正丁基锂 、 三甲基氯硅烷 、 R(+)-alpha-甲基苄胺 、 氢气 、 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 作用下， 以 乙腈 为溶剂， 生成 (R)-3-((S)-1-Benzo[1,3]dioxol-5-yl-2-ethoxycarbonyl-ethylcarbamoyl)-piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Solid-phase parallel synthesis applied to lead optimization: Discovery of potent analogues of the GPIIb/IIIa antagonist RWJ-50042

  摘要：

  A study of beta-turn peptide mimetics, related to the C-terminal gamma-chain of fibrinogen and containing a nipecotic acid scaffold, led to RWJ-50042 (1), an interesting fibrinogen receptor (GPIIb/IIIa) antagonist. To enhance potency, we employed solid-phase parallel synthesis for the preparation of over 200 analogues in a protocol of optimization cycles. This strategy produced several promising nipecotamide analogues, such as 25, which is 35 times more potent than 1 in vitro. Copyright (C) 1996 Elsevier Science Ltd.

  DOI：

  10.1016/0960-894x(96)00438-6